Author(s)

Medyouni Hajar¹, Chouef Jihane¹, Siyouri Oumaima¹, Chbihi Chaymae¹, Mhirech Samia², Amaadour Lamiae¹, Oualla Karima¹, Benbrahim Zineb¹, Arifi Samia¹, Mellas Nawfel¹

¹Department of Medical Oncology, Hassan II University Hospital, Fes, Morocc.
¹Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco.
²Department of Radiotherapy, Hassan II University Hospital, Fes, Morocco.

Osteosarcoma, the most prevalent primary malignant bone tumor in chil-dren, presents significant challenges in treatment, particularly in cases of recurrence or refractory disease. This retrospective study explores the ef-ficacy and safety of gemcitabine-docetaxel (GD) combination therapy as second-line or later treatment in adult patients with advanced bone sarco-mas. Twenty-two patients received GD, with 64% showing overall disease control. Median progression-free survival (PFS) was 5 months, and median overall survival (OS) was 8.5 months. Adverse events were manageable, with mainly myelosuppression observed, principally neutropenia followed by anemia and thrombocytopenia, (grade 1 - 2). Despite limitations such as retrospective design and small sample size, GD demonstrated tolerability and modest efficacy, offering a potential treatment option for refractory or recurrent high-grade osteosarcoma where limited alternatives exist.

Bone sarcomas, Metastatic, Recurrent, Gemcitabine, Docetaxel

Hajar, M. , Jihane, C. , Oumaima, S. , Chaymae, C. , Samia, M. , Lamiae, A. , Karima, O. , Zineb, B. , Samia, A. and Nawfel, M. (2024) Actual Data on the Efficacy and Safety of Gemcitabine-Docetaxel as Second-Line and Beyond Treatment in Adult Patients with Metastatic Bone Sarcomas: Experience from a Single Institution. Open Access Library Journal, 11, 1-6. doi: 10.4236/oalib.1111414.